Antithymocyte globulin used for treatment of severe acute graft versus host disease after haploidentical bone marrow transplantation.
- Author:
Jing LIU
1
;
Heng-Xiang WANG
;
Lian-Ning DUAN
;
Mei XUE
;
Ling ZHU
;
Hong-Min YANG
;
Li DING
;
Shu-Quan JI
Author Information
1. Department of Hematology, Air Force General Hospital of PLA, Beijing 100036, China. liujingemail@126.com
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Antilymphocyte Serum;
administration & dosage;
Bone Marrow Transplantation;
adverse effects;
Child;
Female;
Graft vs Host Disease;
drug therapy;
etiology;
HLA Antigens;
immunology;
Haplotypes;
immunology;
Humans;
Male;
Young Adult
- From:
Journal of Experimental Hematology
2007;15(4):816-818
- CountryChina
- Language:Chinese
-
Abstract:
The objective of study was to investigate the effect of low-dose antithymocyte globulin (ATG) on steroid-resistant severe acute graft versus host disease (aGVHD). Six patients with steroid-resistant severe aGVHD after haploidentical bone marrow transplantation (BMT) received the treatment with ATG at a low dose of 1.25 mg/kg for 3 - 5 doses every other day. The results showed that 3 out of 6 patients got completely remission (CR), among them 2 patients have still been in disease-free survival, 1 patient died from leukemia relapse. 1 out of the other 3 patients got partial remissin (PR), 2 patients were aggravated. The other 3 patients all died from GVHD. The major complications observed in these patients were infections. In conclusion, low-dose ATG is effective for some patients with steroid-resistant severe aGVHD, and has not severe side effect. To strengthen environmental protection should be considered as important for prevention of infection.
